Related Experiment Video
Updated: Jul 9, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Novel peroxisome proliferator activated receptor-alpha agonists
1Department of Atherosclerosis, Institut Pasteur de Lille, and University of Lille 2, Lille, France. Jean-Charles.Fruchart@pasteur-lille.fr
Peroxisome proliferator activated receptors (PPARs) are key to regulating metabolism. Targeting PPARs offers a promising strategy for managing cardiovascular disease and related metabolic disorders.
Area of Science:
- Molecular biology
- Endocrinology
- Cardiovascular medicine
Background:
- Peroxisome proliferator activated receptors (PPARs) are nuclear receptors that regulate gene expression.
- PPARs are crucial in maintaining lipid and glucose homeostasis.
- Dysregulation of these metabolic pathways is linked to cardiovascular disease.
Purpose of the Study:
- To discuss the role of PPARs in treating cardiometabolic abnormalities.
- To highlight PPARs as therapeutic targets for cardiovascular disease.
Main Methods:
- Review of existing literature on PPARs and metabolic regulation.
- Analysis of the involvement of PPARs in lipid metabolism, glucose homeostasis, and inflammation.
Main Results:
- PPARs act as ligand-activated transcription factors.
- PPARs significantly influence lipid metabolism, glucose homeostasis, and inflammatory processes.
- These functions make PPARs critical targets for therapeutic intervention.
Conclusions:
- PPARs are central regulators of key metabolic processes.
- Targeting PPARs presents a viable therapeutic approach for cardiometabolic abnormalities.
- PPAR modulation is a promising strategy for cardiovascular disease management.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...